Skip to main content
SpringerLink
Log in

Endothelin Antagonism and Its Role in the Treatment of Hypertension

  • Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Hypertension contributes greatly to global disease burden and in many patients current treatments do not adequately control blood pressure (BP). Endothelin-1 (ET-1) is a potent vasoconstrictor that is implicated in the pathogenesis of hypertension, including the hypertension that is often associated with chronic kidney disease (CKD) and the metabolic syndrome. ET receptor antagonists, currently licensed for the treatment of pulmonary arterial hypertension and scleroderma-related digital ulcers, are being investigated for the treatment of hypertension. Clinical trials have addressed the use of ET receptor antagonists as monotherapy in primary hypertension, as an add-on therapy in resistant hypertension and in CKD. This review will evaluate the current evidence regarding the therapeutic potential of ET receptor antagonists in hypertension, as well as highlighting important issues that still need to be addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Recently published papers of particular interest have been highlighted as: • Of importance

  1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.

    Article  PubMed  Google Scholar 

  2. Myat A, Redwood SR, Qureshi AC, et al. Resistant hypertension. Br Med J. 2012;345:7.

    Google Scholar 

  3. Foster MC, Rawlings AM, Marrett E, et al. Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States. Am Heart J. 2013. doi:10.1016/j.ahj.2013.03.016.

    PubMed  Google Scholar 

  4. Mendizabal Y, Llorens S, Nava E. Hypertension in metabolic syndrome: vascular pathophysiology. Int J Hyper. 2013. doi:10.1155/2013/230868.

    Google Scholar 

  5. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial-cells. Nature. 1988;332:411–5.

    Article  PubMed  CAS  Google Scholar 

  6. Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family - 3 structurally and pharmacologically distinct isopeptides predicted by 3 separate genes. PNAS 1989,86.

  7. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852–4.

    Article  PubMed  CAS  Google Scholar 

  8. Komuro I, Kurihara H, Sugiyama T, et al. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth-muscle cells. FEBS Lett. 1988;238:249–52.

    Article  PubMed  CAS  Google Scholar 

  9. Dawes KE, Cambrey AD, Campa JS, et al. Changes in collagen metabolism in response to endothelin-1: Evidence for fibroblast heterogeneity. Int J Biochem Cell Biol. 1996;28:229–38.

    Article  PubMed  CAS  Google Scholar 

  10. Halcox JPJ, Nour KRA, Zalos G, Quyyumi AA. Coronary vasodilation and improvement in endothelial dysfunction with endothelin ETA receptor blockade. Circ Res. 2001;89:969–76.

    Article  PubMed  CAS  Google Scholar 

  11. Vuurmans TJL, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension. 2003;41:1253–8.

    Article  PubMed  CAS  Google Scholar 

  12. Shohet RV, Kisanuki YY, Zhao XS, et al. Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. PNAS. 2004;101:2088–93.

    Article  PubMed  CAS  Google Scholar 

  13. Attina T, Camidge R, Newby DE, Webb DJ. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart. 2005;91:825–31.

    Article  PubMed  CAS  Google Scholar 

  14. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial-cells. J Biol Chem. 1992;267:16066–8.

    PubMed  CAS  Google Scholar 

  15. Arai H, Hori S, Aramori I et al. Cloning and expression of a cDNA-encoding an endothelin receptor. Nature 1990,348.

  16. Sakamoto A, Yanagisawa M, Sakurai T et al. Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem Biophys Res Comm 1991,178.

  17. Davenport AP, Oreilly G, Kuc RE. Endothelin ETA and ETB messenger-rna and receptors expressed by smooth-muscle in the human vasculature - majority of the ETA sub-type. Br J Pharmacol. 1995;114:1110–6.

    Article  PubMed  CAS  Google Scholar 

  18. Karet FE, Kuc RE, Davenport AP. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 1993;44:36–42.

    Article  PubMed  CAS  Google Scholar 

  19. Herrera M, Garvin JL. Endothelin stimulates endothelial nitric oxide synthase expression in the thick ascending limb. Am J Physiol. 2004;287:F231–5.

    CAS  Google Scholar 

  20. Johnstrom P, Fryer TD, Richards HK, et al. Positron emission tomography using F-18-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ETB receptors in vivo. Br J Pharmacol. 2005;144:115–22.

    Article  PubMed  Google Scholar 

  21. Maguire JJ, Kuc RE, Davenport AP. Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues. Life Sci. 2012;91:681–6.

    Article  PubMed  CAS  Google Scholar 

  22. Goddard J, Webb DJ. Endothelin antagonists and hypertension: A question of dose? Hypertension. 2002;40:E1–2.

    Article  PubMed  CAS  Google Scholar 

  23. Schiffrin EL. Vascular endothelin in hypertension. Vasc Pharmacol 2005,43.

  24. Mortensen LH, Pawloski CM, Kanagy NL, Fink GD. Chronic hypertension produced by infusion of endothelin in rats. Hypertension. 1990;15:729–33.

    Article  PubMed  CAS  Google Scholar 

  25. Pollock DM, Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol. 2001;281:F144–50.

    CAS  Google Scholar 

  26. Mortensen LH, Fink GD. Salt-dependency of endothelin-induced, chronic hypertension in conscious rats. Hypertension. 1992;19:549–54.

    Article  PubMed  CAS  Google Scholar 

  27. Moreau P. Endothelin in hypertension: A role for receptor antagonists? Cardiovasc Res. 1998;39:534–42.

    Article  PubMed  CAS  Google Scholar 

  28. Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin level in patients with essential-hypertension. New Engl J Med 1990,322.

  29. Cody RJ, Haas GJ, Binkley PF et al. Plasma endothelin correlates with the extent of pulmonary-hypertension in patients with chronic congestive-heart-failure. Circulation 1992,85.

  30. Davenport AP, Ashby MJ, Easton P, et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma - comparison of levels in patients with essential-hypertension and normotensive control subjects. Clin Sci. 1990;78:261–4.

    PubMed  CAS  Google Scholar 

  31. Schiffrin EL, Thibault G. Plasma endothelin in human essential-hypertension. Am J Hyper. 1991;4:303–8.

    CAS  Google Scholar 

  32. Fukuroda T, Fujikawa T, Ozaki S et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994,199.

  33. Cardillo C, Kilcoyne CM, Waclawiw M, et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension. 1999;33:753–8.

    Article  PubMed  CAS  Google Scholar 

  34. Martin P, Ninio D, Krum H. Effect of endothelin blockade on basal and stimulated forearm blood flow in patients with essential hypertension. Hypertension. 2002;39:821–4.

    Article  PubMed  CAS  Google Scholar 

  35. Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. New Engl J Med. 1998;338:784–90.

    Article  PubMed  CAS  Google Scholar 

  36. Rohmeiss P, Birck R, Braun C, et al. Pharmacology of the endothelin A receptor antagonist: LU 135252. Cardiovasc Drug Rev. 1998;16:391–412.

    Article  CAS  Google Scholar 

  37. Nakov R, Pfarr E, Eberle S, Investigators H. Darusentan: An effective endothelin A receptor antagonist for treatment of hypertension. Am J Hyper. 2002;15:583–9.

    Article  CAS  Google Scholar 

  38. Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hyper. 2007;9:760–9.

    Article  CAS  Google Scholar 

  39. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1423–31.

    Article  PubMed  CAS  Google Scholar 

  40. • Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824–30. A large clincal trial where the decrease in BP with an ET A R selective antagonist was similar to placebo. This result terminated any future studies.

    Article  PubMed  CAS  Google Scholar 

  41. Webb DJ. DORADO: opportunity postponed lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. Hypertension. 2010;56:806–7.

    Article  PubMed  CAS  Google Scholar 

  42. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357:1601–8.

    Article  PubMed  CAS  Google Scholar 

  43. Vaneckova I, Kramer HJ, Backer A, et al. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension. 2005;46:969–74.

    Article  PubMed  CAS  Google Scholar 

  44. Koyama H, Nishzawa Y, Morii H, et al. Plasma endothelin levels in patients with uremia. Lancet. 1989;1:991–2.

    Article  PubMed  CAS  Google Scholar 

  45. Goddard J, Johnston NR, Cumming AD, Webb DJ. Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade. Am J Physiol. 2007;293:F1433–8.

    CAS  Google Scholar 

  46. Orisio S, Benigni A, Bruzzi I, et al. Renal endothelin gene-expression is increased in remnant kidney and correlates with disease progression. Kidney Int. 1993;43:354–8.

    Article  PubMed  CAS  Google Scholar 

  47. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure - A comparison of selective and combined endothelin receptor blockade. Circulation. 2004;109:1186–93.

    Article  PubMed  CAS  Google Scholar 

  48. Dhaun N, MacIntyre IM, Melville V, et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension. 2009;54:U113–U71.

    Article  Google Scholar 

  49. Wu CD, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem. 1997;40:1690–7.

    Article  PubMed  CAS  Google Scholar 

  50. • Dhaun N, MacIntyre IM, Kerr D, et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011;57:772. Reduction in blood pressure and cardiovascular risk factors with chronic ET A R selective antagonism in CKD.

    Article  PubMed  CAS  Google Scholar 

  51. Sarafidis PA, Bakris GL. Review: Insulin and endothelin: An interplay contributing to hypertension development? J Clin Endocrin Metabol. 2007;92:379–85.

    Article  CAS  Google Scholar 

  52. Formoso G, Chen H, Kim JA, et al. Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol. 2006;20:1153–63.

    Article  PubMed  CAS  Google Scholar 

  53. van Harmelen V, Eriksson A, Astrom G, et al. Vascular peptide endothelin-1 links fat accumulation with alterations of visceral adipocyte lipolysis. Diabetes. 2008;57:378–86.

    Article  PubMed  Google Scholar 

  54. Wolpert HA, Steen SN, Istfan NW, Simonson DC. Insulin modulates circulating endothelin-1 levels in humans. Metabolism. 1993;42:1027–30.

    Article  PubMed  CAS  Google Scholar 

  55. Juan CC, Shen YW, Chien Y, et al. Insulin infusion induces endothelin-1-dependent hypertension in rats. Am J Physiol. 2004;287:E948–54.

    CAS  Google Scholar 

  56. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002;106:1783–7.

    Article  PubMed  CAS  Google Scholar 

  57. Shemyakin A, Bohm F, Wagner H, et al. Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance. J Cardiovasc Pharmacol. 2006;47:385–90.

    PubMed  CAS  Google Scholar 

  58. Amiri F, Virdis A, Neves MF, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation. 2004;110:2233–40.

    Article  PubMed  CAS  Google Scholar 

  59. Saleh MA, Boesen EI, Pollock JS, et al. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension. 2010;56:U942–427.

    Article  Google Scholar 

  60. Barton M, Haudenschild CC, D'Uscio LV, et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. PNAS. 1998;95:14367–72.

    Article  PubMed  CAS  Google Scholar 

  61. Teerlink JR, Loffler BM, Hess P, et al. Role of endothelin in the maintenance of blood-pressure in conscious rats with chronic heart-failure—acute effects of the endothelin receptor antagonist RO-47-0203 (bosentan). Circulation. 1994;90:2510–8.

    Article  PubMed  CAS  Google Scholar 

  62. Humbert M, Segal ES, Kiely DG, et al. Results of european post-marketing surveillance of bosentan in pulmonary hypertension. Eur Resp J. 2007;30:338–44.

    Article  CAS  Google Scholar 

  63. Ben-Yehuda O, Pizzuti D, Brown A, et al. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2012;60:80–1.

    Article  PubMed  CAS  Google Scholar 

  64. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Resp Crit Care Med. 2004;169:441–7.

    Article  PubMed  Google Scholar 

  65. Kohan D, Strait K, Stricklett P et al. Identification of the site of endothelin a receptor antagonist-induced fluid retention. Hypertension 2011,58:E155-E.

    Google Scholar 

  66. Liu X, He L, Dinger B, et al. Effect of endothelin receptor antagonist bosentan on chronic hypoxia-induced inflammation and chemoafferent neuron adaptation in rat carotid body. High Alt Med Biol. 2012;13:209–16.

    Article  PubMed  CAS  Google Scholar 

  67. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally-active nonpeptide endothelin receptor antagonist. J Pharmaocl Exp Ther. 1994;270:228–35.

    CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Rebecca C. Moorhouse declares that she has no conflict of interest. David J. Webb has served as a consultant to and received grants from Pfizer. David C. Kluth declares that he has no conflict of interest. Neeraj Dhaun has received grants from Pfizer.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Centre for Cardiovascular Science, University of Edinburgh, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK

    Rebecca C. Moorhouse, David J. Webb & Neeraj Dhaun

  2. Centre for Inflammation Research, University of Edinburgh, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK

    David C. Kluth & Neeraj Dhaun

  3. The Queen’s Medical Research Institute, 3rd Floor East, Room C3.29 47 Little France Crescent, Edinburgh, EH16 4TJ, UK

    Neeraj Dhaun

Authors
  1. Rebecca C. Moorhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Webb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David C. Kluth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Neeraj Dhaun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neeraj Dhaun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moorhouse, R.C., Webb, D.J., Kluth, D.C. et al. Endothelin Antagonism and Its Role in the Treatment of Hypertension. Curr Hypertens Rep 15, 489–496 (2013). https://doi.org/10.1007/s11906-013-0380-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-013-0380-1

Keywords

Search

Navigation